This was the stock's second consecutive day of losses.

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Kenvue beat Q1 sales estimates and updated its 2025 forecast as it manages foreign exchange impacts, tariffs, and leadership ...

In its fiscal second quarter of 2025, ended March 31, Visa delivered a 9% increase in revenue and a 10% increase in non-GAAP ...

Discover Kenvue's Q1 2025 earnings insights—strategic growth, tariff mitigation, innovation focus, and supply chain resilience to drive performance this year.

Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds.

Shares of Kenvue Inc. KVUE slid 1.80% to $24.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 and the ...